PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness

PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness

Introduction Sitagliptin is a dipeptidyl peptidase 4 inhibitor for the treatment of type 2 diabetes (T2D). Limited real-world data on its effectiveness and safety are available from an Italian population.Research design and methods We evaluated long-term clinical data from the single-arm PERsistent...

Full description

Bibliographic Details
Main Authors: Antonio Carlo Bossi, Valentina De Mori, Carlotta Galeone, Davide Pietro Bertola, Margherita Gaiti, Annalisa Balini, Denise Berzi, Franco Forloni, Giancarla Meregalli, Federica Turati
Format: Article
Language:English
Published: BMJ Publishing Group 2020-04-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/8/1/e001507.full

Internet

https://drc.bmj.com/content/8/1/e001507.full

Similar Items